Lenhard Justin R, von Eiff Christof, Hong Irene S, Holden Patricia N, Bear Michael D, Suen Amy, Bulman Zackery P, Tsuji Brian T
Laboratory for Antimicrobial Pharmacodynamics, NYS Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, Buffalo, New York, USA School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
Institute of Medical Microbiology, University of Munster, Munster, Germany.
Antimicrob Agents Chemother. 2015 Feb;59(2):1347-51. doi: 10.1128/AAC.04508-14. Epub 2014 Dec 1.
Staphylococcus aureus small-colony variants (SCVs) often persist despite antibiotic therapy. Against a 10(8)-CFU/ml methicillin-resistant S. aureus (MRSA) (strain COL) population of which 0%, 1%, 10%, 50%, or 100% was an isogenic hemB knockout (Ia48) subpopulation displaying the SCV phenotype, vancomycin achieved maximal reductions of 4.99, 5.39, 4.50, 3.28, and 1.66 log10 CFU/ml over 48 h. Vancomycin at ≥16 mg/liter shifted a population from 50% SCV cells at 0 h to 100% SCV cells at 48 h, which was well characterized by a Hill-type model (R2>0.90).
金黄色葡萄球菌小菌落变体（SCVs）通常在抗生素治疗后仍会持续存在。对于每毫升含10⁸ 菌落形成单位（CFU）的耐甲氧西林金黄色葡萄球菌（MRSA）（菌株COL）群体，其中0%、1%、10%、50%或100%为显示SCV表型的同基因hemB基因敲除（Ia48）亚群体，在48小时内，万古霉素实现的最大菌量减少分别为4.99、5.39、4.50、3.28和1.66 log₁₀ CFU/ml。≥16毫克/升的万古霉素使群体在0小时时50%为SCV细胞转变为48小时时100%为SCV细胞，这可以用希尔型模型很好地描述（决定系数R²>0.90）。
